Fig. 1.

Disposition of agalsidase alfa–treated patients. The All Treated cohort of FOS was subdivided into an Evaluable Treated cohort and then further subdivided into Evaluable Treated Morbidity (and mortality), Renal, and Cardiac cohorts for comparison with untreated patients (shaded boxes) from studies by Banikazemi et al. [20], Kampmann et al. [8], and Schiffmann et al. [21]. eGFR, estimated glomerular filtration rate; F, female; FOS, Fabry Outcome Survey; LVMI, left ventricular mass indexed to height; M, male.